Szeto Cheuk-Chun, Kwan Bonnie Ching-Ha, Chow Kai-Ming, Law Man-Ching, Pang Wing-Fai, Chung Kwok-Yi, Leung Chi-Bon, Li Philip Kam-Tao
Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Am J Kidney Dis. 2009 Oct;54(4):702-10. doi: 10.1053/j.ajkd.2009.04.032. Epub 2009 Jul 4.
The clinical behavior and optimal treatment of relapsing and recurrent peritonitis episodes in patients undergoing long-term peritoneal dialysis are poorly understood.
Retrospective study over 14 years.
SETTING & PARTICIPANTS: University dialysis unit; 157 relapsing episodes (same organism or culture-negative episode occurring within 4 weeks of completion of therapy for a prior episode), 125 recurrent episodes (different organism, occurs within 4 weeks of completion of therapy for a prior episode), and 764 control episodes (first peritonitis episode without relapse or recurrence).
Exit-site infection, empirical antibiotics.
Primary response (resolution of abdominal pain, clearing of dialysate, and peritoneal dialysis effluent neutrophil count < 100 cells/mL after 10 days of antibiotic therapy), complete cure (resolution by using antibiotics without relapse/recurrence), catheter removal (for any cause while on antibiotic therapy), and mortality.
Compared with the control group, more relapsing episodes were caused by Pseudomonas species (16.6% versus 9.4%) and were culture negative (29.9% versus 16.4%); recurrent infections commonly were caused by Enterococcus species (3.2% versus 1.2%) or other Gram-negative organisms (27.2% versus 11.1%) or had mixed bacterial growth (17.6% versus 12.7%). There were significant differences in primary response, complete cure, and mortality rates among groups (P < 0.001 for all comparisons). Compared with the control and relapsing groups, post hoc analysis showed that the recurrent group had a significantly lower primary response rate (86.4%, 88.5%, and 71.2%, respectively), lower complete cure rate (72.3%, 62.4%, and 42.4%, respectively), and higher mortality rate (7.7%, 7.0%, and 20.8%, respectively).
Retrospective analysis.
Relapsing and recurrent peritonitis episodes are caused by different spectra of bacteria and probably represent 2 distinct clinical entities. Recurrent peritonitis episodes had a worse prognosis than relapsing ones.
长期接受腹膜透析的患者复发性和反复性腹膜炎发作的临床行为及最佳治疗方法尚不清楚。
为期14年的回顾性研究。
大学透析科;157例复发病例(同一病原体或在先前一次发作治疗结束后4周内出现的培养阴性发作),125例反复发病例(不同病原体,在先前一次发作治疗结束后4周内出现),以及764例对照病例(首次腹膜炎发作且无复发或反复)。
出口处感染、经验性抗生素使用。
主要反应(抗生素治疗10天后腹痛缓解、透析液澄清且腹膜透析流出液中性粒细胞计数<100个/毫升)、完全治愈(使用抗生素后症状缓解且无复发/反复)、因任何原因在抗生素治疗期间拔除导管以及死亡率。
与对照组相比,复发病例中由假单胞菌属引起的比例更高(16.6%对9.4%),且培养阴性的比例更高(29.9%对16.4%);反复感染通常由肠球菌属(3.2%对1.2%)或其他革兰氏阴性菌(27.2%对11.1%)引起,或有混合细菌生长(17.6%对12.7%)。各组间主要反应、完全治愈及死亡率存在显著差异(所有比较P<0.001)。事后分析显示,与对照组和复发病例组相比,反复发病例组的主要反应率显著更低(分别为86.4%、88.5%和71.2%),完全治愈率更低(分别为72.3%、62.4%和42.4%),死亡率更高(分别为7.7%、7.0%和20.8%)。
回顾性分析。
复发性和反复性腹膜炎发作由不同种类的细菌引起,可能代表两种不同的临床实体。反复性腹膜炎发作的预后比复发性更差。